Additionally, COMP expression is associated with increased tumor invasiveness through integrin binding [12]; inhibiting avβ3 and avβ5 receptors using cilengitide in DU145 cells treated with COMP reduced COMP-mediated integrin activation of the FAK/Src/AKT pathway [20], lowering invasion [12]. The gene discussed is COMP; the disease is neoplasm.